Cambrio Publishes Pathfinder Prospectus

23 June 1996

A new UK-based pharmaceutical company, Cambrio, has been launched in London, with the publishing of its pathfinder prospectus ahead of a listing on the London Stock Exchange next month.

The firm is the brainchild of Nowell Stebbing, who steered another UK biotechnology company, Chiroscience, through a flotation in 1994, raising L45 million ($69 million; Marketletters passim).

Cambrio says it provides skilled technical services to the international drug industry, manufactures and distributes specialist products to niche markets, develops and manufactures branded medicinal products, and is researching and developing a new generation of medicinal products from plant extracts.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight